Kymera Therapeutics, Inc. (NASDAQ:KYMR) is a biopharmaceutical company focused on developing novel protein degradation therapies. Operating in the Zacks Medical - Biomedical and Genetics industry, Kymera aims to address diseases with high unmet medical needs. The company faces competition from other biotech firms working on innovative treatments. On November 4, 2025, Morgan Stanley updated its rating for Kymera to "Overweight," with the stock priced at $59.91. The price target was also raised from $70 to $73.
Despite the positive rating from Morgan Stanley, Kymera's recent financial performance presents challenges. In its Q3 2025 earnings call, the company reported a quarterly loss of $0.90 per share, exceeding the Zacks Consensus Estimate of a $0.71 loss. This represents a 26.76% negative surprise, as highlighted by Zacks. The loss is also larger than the $0.82 per share loss from the same quarter last year.
Revenue figures for Kymera also fell short of expectations. The company posted $2.76 million in revenue for the quarter ending September 2025, missing the Zacks Consensus Estimate by 89.6%. This is a decline from the $3.74 million reported in the same quarter the previous year. Over the past four quarters, Kymera has only exceeded consensus revenue estimates once.
The stock's current price of $59.91 reflects a slight increase of 0.32% or $0.19. Throughout the day, KYMR has fluctuated between $55.66 and $61.30. Over the past year, the stock has seen a high of $63.96 and a low of $19.45. With a market capitalization of approximately $4.28 billion, Kymera remains a significant player in its industry. Today's trading volume for KYMR is 816,036 shares.
